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Abstract 
 
Purpose 
 The purpose of this clinical review is to determine if induced therapeutic hypothermia is 
effective in reducing neurological deficits and mortality in cardiac arrest patients. 
Methods 
 PubMed, Cochrane Review Database, Embase, and Trip database were utilized. A 
common set of search terms including "induced hypothermia", "therapeutic hypothermia”, 
"cardiovascular resuscitation", “cardiac arrest”, "neurological deficits", “neurological outcome” 
and “mortality” guided the search. A total of three individual studies that were included for final 
results review. 
Results 
 Clinically based trials revealed that induced therapeutic hypothermia can improve both 
survival rates and neurological outcomes in cardiac arrest patients compared to cardiac arrest 
patients that do not receive therapeutic hypothermia.   
Conclusion 
 Although more research needs to be done to make therapeutic hypothermia implemented 
across all cardiac arrest patients, current research has suggested that therapeutic hypothermia 
implantation in cardiac arrest protocols can prove to be extremely beneficial in improving patient 
survival rates and neurological outcome
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Introduction 
 Death rates among patients that suffer sudden cardiac arrest out of hospital are high. In 
the United States alone, more than 350,000 individuals had in incidence of out of hospital 
cardiac arrest in 2016.10 Out of these 350,000 patients that suffered cardiac arrest, ~200,000 of 
them resulted in death. This clinical condition affects many individuals without warning as it is 
difficult to predict. One adverse effect of cardiac arrest is persistent neurological deficits as a 
consequence of spontaneous reperfusion. Surviving with good neurological outcome is difficult 
to achieve and experimental evidence proposes that therapeutic hypothermia is beneficial11. 
Research has suggested that therapeutic hypothermia implantation in cardiac arrest protocols can 
prove to be extremely supportive in giving the patient the very best neurological outcome.  
  The concept of therapeutic hypothermia has been around for over 2000 years and while 
the principle has advanced since then, there is still research that needs to be done to establish 
guidelines for its widespread implementation. With the continuous advances in medicine there is 
no set limit to how it can drastically change our patients outcomes for the better. In the 
meantime, while we can continue to work to keep ourselves as healthy as possible, cardiac arrest 
can still happen. It is what happens after cardiac arrest that can be improved, and by improving 
that we can improve survival rates as well as quality of life.  
Background 
History of Therapeutic Hypothermia 
 While therapeutic hypothermia may seem futuristic, it has been around far longer than 
one would think. Even though it’s not quite what you would think in terms of a cryocooling 
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chamber suspending one’s animation in time while medical staff races to find a cure like a sci-fi 
movie would suggest, medicine still has made great advances since it was first introduced. The 
concept of therapeutic hypothermia has been used dating all the way back to the father of 
medicine himself, Hippocrates. He saw the value of it and mentioned the use of snow and ice to 
reduce hemorrhage in his wounded and critically ill patients.1  
 This treatment has emerged continually throughout history. In 1954 a study by Rosomoff 
and Holaday2 found a surprising fall in cerebral oxygen consumption in dogs that underwent 
therapeutic hypothermia. They documented this decrease in oxygen consumption occurred when 
the dogs temperatures were lowered from 35°C to 26°C. Furthermore, it was found that there 
was an astonishing three-fold reduction in oxygen consumption when the dogs were cooled 
down to 26°C2. Through their experiments and others that followed, this helped catalyze what 
would then lead to predictions in how this concept could be used in human medicine. With these 
studies, it could predict how it could be used for cardiac arrest patients.  
 In 1958 the very first study on humans using therapeutic hypothermia was conducted 
with cardiac arrest patients3. The study suggested decreased mortality in the patients that 
received that therapeutic hypothermia. Although this study did not look at neurological outcome 
in these patients. This groundbreaking study included 19 patients that were resuscitated after 
suffering perioperative cardiac arrest. All patients had their thoracic cavity opened and their heart 
was documented to be in fibrillation or asystole. Then the subjects that were chosen for 
therapeutic hypothermia were cooled using a circulating coolant blanket. The subjects were 
cooled and maintained at approximately 31–32°C.3 There was no set time that the subjects were 
cooled, and clinical judgment was used to determine the duration of hypothermia. Although, 
when improvement was noted, hypothermia was gradually stopped. The subjects were then 
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slowly and gradually returned to normal temperature. It was discovered that out of the 19 
patients included in the study, 7 patients in the control group did not receive therapeutic 
hypothermia, while 12 patients in the treatment group received therapeutic hypothermia.3 The 
conclusion showed that the survival rate was 50 percent in the treatment group compared to 14 
percent in the control group.  
 Although the outcomes of utilizing therapeutic hypothermia to improve survival of 
cardiac arrest were very promising, until twenty years ago few studies on the treatment existed. 
The studies that were published documented favorable results and in 2002 the advisory panel 
from the International Liaison Committee on Resuscitation (ILCOR) implemented the 
recommendation of its use in common practice.  In 2002, two studies were published out of 
Europe4 and Australia5 that demonstrated improved survival rates and improved neurological 
outcomes when using mild therapeutic hypothermia. The studies studied that effect of 
therapeutic hypothermia on comatose survivors of Out of Hospital Cardiac Arrest (OHCA) that 
were due to Ventricular Fibrillation (VF). The Hypothermia after Cardiac Arrest Study Group 
(HACA), including nine hospitals in five European countries, showed that mild hypothermia 
(cooling to 32–34ºC for 24 h) in 274 OHCA patients with return of spontaneous circulation 
(ROSC) provided significant improvement in functional recovery and good neurological 
outcome after hospital discharge (55% vs. 39%).5 It also led to a lower 6-month mortality rate 
when compared with patients who were not cooled (41% vs. 55%).5  In Australia, Bernard et al. 
examined the endpoint of survival to hospital discharge in 77 patients.4 This showed a 49% 
survival rate in the therapeutic hypothermia group which were cooled to 33°C for 12 hours, 
compared to a survival rate of 26% in the group that did not receive therapeutic hypothermia.4   
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 Even though there were published guidelines in by the International Liaison Committee 
on Resuscitation (ILCOR) supporting the use of therapeutic hypothermia6 in 2005, the use of 
hypothermia as treatment still lagged in utilization. Adoption of hypothermia in North America 
was even slower with far higher utilization rates in North European countries.7 There were many 
different reasons for its delay in implementation. These reasons included insufficient knowledge 
of effective hypothermia techniques, lack of belief that therapeutic hypothermia would improve 
the outcome for individual patients, and controversies regarding the best method to reach the 
target temperatures6.  
 The ILCOR guidelines in 2005 did not clarify a set cooling protocol. In 2010, newer 
guidelines were published by the International Liaison Committee on Resuscitation (ILCOR)8. 
This progressive advancement by the ILCOR helped provide the material for the American Heart 
Association (AHA)9 to write their new resuscitation guidelines in 2010. Now with the AHA 
advocating for the implementation of the use of therapeutic hypothermia, there was a higher 
likelihood that therapeutic hypothermia would be utilized in North America to truly see how it 
could impact cardiac arrest patient outcomes. While it may have started with the father of 
medicine more than 2000 years ago, with some modern improvisation, therapeutic hypothermia 
will continue to strive to benefit patient outcomes.  
Physiology of Therapeutic Hypothermia 
 The act of simply “cooling” a patient seems almost elementary in comparison to other 
lifesaving procedures that occur during cardiac arrest resuscitation. While it may seem that way 
at first, after considering what the active cooling does to the patient’s individual systems it 
uncovers itself to be quite complex. That is the exquisite nature of the physiology of therapeutic 
hypothermia. It effects each organ system and body mechanisms differently. During cardiac 
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arrest, there is secondary damage to the brain and other vital organs due to hypoperfusion that 
can ultimately lead to neurological deficits and death. Therapeutic hypothermia is being used to 
improve this secondary impact that causes profound damage to the brain and other organ tissue. 
Unfortunately, what is not yet fully understood is the complete mechanism of action of 
hypothermia and how it effects every organ system differently. This is due to how incredibly 
complex it is. Although, research has been conducted to further understand how something like 
hypothermia works to help individuals from this secondary damage.  
 Therapeutic hypothermia and its protective effects on the body, especially from 
secondary damage can be broken down into several pathways. A decreased metabolic state 
resulting in lower oxygen and energy consumption along with carbon dioxide production may 
prevent secondary injury when oxygen supply is interrupted or, at least, impaired.12 This is 
especially important with patients suffering from cardiac arrest. Regardless if a patient suffers 
cardiac arrest out of hospital or in hospital there will almost always be a period when their 
oxygen supply to the brain is interrupted. When there is no oxygenation through ventilation this 
causes delayed perfusion to the brain and organ tissues. After the oxygen supply has been 
interrupted and then reintroduced this causes a rush of oxygenated blood. This rush of re 
oxygenated blood while necessary, can cause reperfusion injury. Therapeutic hypothermia has 
been speculated and studied to demonstrate protection against such reperfusion injuries through 
various mechanisms. 13 In 2003 a study was published that went to explain some of these cellular 
pathways.  
 Among the many cellular pathways that may be responsible for the beneficial effects of 
cooling, a central hypothesis is that hypothermia reduces cellular metabolism and oxygen 
demand while maintaining acceptable ATP levels.14 Additionally, hypothermia attenuates 
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abnormal free radical production, improves cellular ion handling, and improves cellular pH 
balance.15 Hypothermia also reduces cell death and inflammatory signaling.16  Reperfusion 
following ischemia results in a short period of excessive free radical production. Reperfusion-
induced free radical production suggests that reperfusion injury is mediated by oxidative stress.18 
Studies suggest that the mitochondrial electron transport chain is an important site of post-
reperfusion free radical generation.13 Mitochondrial free radical production is an important target 
mechanism during the first window of opportunity for hypothermia treatment. This window 
likely requires the initiation of therapeutic hypothermia during the active cardiac arrest so that 
when spontaneous reperfusion is finally obtained the blood that is circulating is already cooled.  
 A second window of opportunity for hypothermia after reperfusion injury targets the 
inflammatory cascade and cell death pathways known as apoptosis and necrosis. After a patient’s 
oxygen supply is interrupted, apoptotic processes may be initiated in brain tissue and neuronal 
cells may start to die and become necrotic. In these earliest stages these pathways may be 
blocked by hypothermia.12 This second window lasts several hours and is targeted by our current 
clinical practice of initiating therapeutic hypothermia after spontaneous reperfusion. Lampe, J. 
W., et al. illustrated this concept of the effects of hypothermia on reperfusion injury. As shown in 
Figure 1, initiation of therapeutic hypothermia after spontaneous reperfusion occurs offers 
protection but is considered to only help with  
later cell death and inflammatory 
 signaling. The illustration also shows 
 that initiation of therapeutic hyperthermia  
during active cardiac arrest and before  
spontaneous reperfusion, is considered  
Figure 1: Lampe, J. W., & Becker, L. B. (2011). State 
of the art in therapeutic hypothermia. Annual review of 
medicine, 62, 79-93.	
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to target cellular abnormalities that are induced by ischemia as well as cell signaling after 
spontaneous reperfusion is obtained.  
 Ischemia reperfusion injury can also lead to significant disruptions in the blood-brain 
barrier. This disruption can initiate the development of brain edema in patients which can be 
problematic. The use of therapeutic hypothermia can significantly reduce the blood-brain barrier 
disruption, and also can decrease the vascular permeability following ischemia reperfusion. This 
in hand, can decrease the brain edema from forming.17 Other studies such as the Eurotherm3235 
Trial ISRCTN34555414 have branched off from this evidence to use therapeutic hypothermia to 
reduce secondary brain injury and thus the development of cerebral edema or prophylactic 
hypothermia.19 Also, the use of rescue hypothermia as an exact treatment of raised intracranial 
pressure. This showed that therapies such as therapeutic hypothermia that reduce intracranial 
pressure also improve neurological outcome. Nevertheless, the association between controlled 
intracranial pressure and exactly how it can improve neurological outcome is still uncertain.20 
Appendix B further summarizes the changes to the blood-brain barrier and intracranial pressure 
related to therapeutic hypothermia.       
 Until the 1990s, it was presumed that the neurological protective effects of hypothermia 
were exclusively due to a reduction in cerebral metabolism.21 Even though there is a distinct 
decrease in metabolism, it is now understood that this decrease is only one of numerous 
mechanisms behind the protective effects of hypothermia. In therapeutic hypothermia when the 
patients core temperature drops and the metabolic rate decreases, glucose and oxygen 
consumption, as well as carbon dioxide production also decrease. This helps prevent or decrease 
injury when oxygen supply is interrupted or limited. It is important to note that this reduction in 
metabolic rate due to therapeutic hypothermia may require there to be needed adjustments made 
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in ventilator settings to ensure a patient maintains normal arterial carbon dioxide pressures.17 
Since glucose consumption decreases as well as insulin sensitivity, this may also require needed 
adjustments in insulin infusion rates. The rate of these changes depends on how quickly a patient 
was cooled due to therapeutic hypothermia induction.22  
 A patient’s electrolytes are also affected by therapeutic hypothermia due to intracellular 
shift and tubular dysfunction. When considering that low magnesium and potassium levels can 
elevate the risk of arrhythmias, and low levels of phosphate can increase the risk of infection it is 
important to maintain these electrolytes on the higher end of normal range during and after 
initiation of therapeutic hypothermia.19 When potassium supplementation is administered during 
the cooling it is important to be aware of the possibility of rebound hyperkalaemia that is a risk 
during the rewarming phase. Cooling can also have effects on intracellular/extracellular acidosis 
and cellular metabolism. The reduction in cell membrane integrity, ion-pump failure, 
mitochondrial dysfunction, and cellular hyperactivity all contribute to the development of 
intracellular acidosis which stimulates many of these harmful processes.19 The risk of these 
potentially harmful processes can be lessened by the use of therapeutic hypothermia. Appendix B 
further summarizes the changes to metabolism and electrolytes related to therapeutic 
hypothermia. 
 Cardiovascular changes and hemodynamic effects occur as well during therapeutic 
hypothermia. The effects of cooling on the myocardium and its contractility moderately depend 
on the patient’s volume status and capability of sedation. This decrease in metabolic rate usually 
matches or exceeds the reduction in cardiac output which then maintains or improves the 
equilibrium between supply and demand.22 After therapeutic hypothermia has been initiated there 
is an expected decrease in heart rate by 40-50bpm that occurs at lower core temperatures of 33◦C; 
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it is generally advisable to allow this occur and to not attempt to increase heart rate 
pharmacologically. Since myocardial contractility improves when heart rate is decreased during 
therapeutic hypothermia, if heart rate is artificially increased it can decrease myocardial 
contractility.23 In regards to coronary perfusion, cooling can provide protection for ischemic 
myocardium, although patients with preexisting coronary artery disease may not receive this 
protection. There is preliminary evidence available that suggests that early initiation of 
therapeutic hypothermia after myocardial infarction may help lessen subsequent myocardial 
injury.21 Appendix B further summarizes the changes to heart function as well as other 
mechanisms of action, risks and changes to body regulations related to therapeutic hypothermia. 
Methodology 
 PubMed, Cochrane Review Database, Embase, and Trip database, were utilized. The 
search terms "induced hypothermia", "therapeutic hypothermia”, "cardiovascular resuscitation", 
“cardiac arrest”, "neurological deficits", “neurological outcome” and “mortality” guided the 
literature search. Please see appendix A for Mesh terms. Supplemental resources included JAMA 
evidence, Society of Emergency Medicine Physician Assistants (SEMPA), and UpToDate, 
utilized to provide background information and provide structure for further searches. Excluded 
studies in my review included those that were: not randomized clinical trials, studies that did not 
focus on neurological outcomes or survival rates, studies that only focused on optimal target 
temperature management, studies on animals, studies focusing on timing of neurologic 
prognostication, studies focusing solely on adverse events, studies focusing on other initial 
arrhythmias than ventricular in nature, and studies focusing on therapeutic hypothermia’s effects 
on cardioprotection. To be included for final review the articles chosen were randomized clinical 
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trials, written in English, and published within the last 15 years. There were 3 final individual 
studies that were included for a final results review.  
Review of Literature Results 
Holzer at al. 
 Holzer at al. in association with the HACA (The Hypothermia After Cardiac Arrest Study 
Group) conducted a RCT study with 275 patients. They sought to understand in patients with 
cardiac arrest due to VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia), 
whether mild hypothermia improve neurologic outcomes compared with standard care 
normothermia. Their study design was a randomized, controlled trial with blinded assessment of 
the outcome. The patients were then randomly assigned to either the hypothermia group or the 
normothermia group (received standard care after resuscitation).5 137 of the patients were 
randomly assigned to the hypothermia group and 138 to the normothermia group. Unfortunately, 
14 patients were discontinued early in the hypothermia group due to a variety of reasons 
including: death, arrhythmias, hemodynamic instability, cooling device technical problems, liver 
rupture, and assignment/cooling errors. All of the randomized patients were included in the 
analysis of mortality.5  
 To be eligible in the study the patient had to meet the following criteria: witnessed 
cardiac arrest, ventricular fibrillation or pulseless ventricular tachycardia as the initial cardiac 
rhythm, presumed	cardiac origin of the arrest, age of 18 to 75 years, estimated	interval of 5 to 15 
minutes from the witness of patient’s collapse to the first	attempt at resuscitation by emergency 
medical personnel, and an	interval of no more than 60 minutes from collapse to restoration	of 
spontaneous circulation. The exclusion criteria were quite extensive. Patients were excluded if 
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they met any of the following criteria: tympanic-membrane temperature below 30°C on 
admission, a comatose state before the cardiac arrest due to the administration of anesthetic 
medications, pregnancy, response to verbal commands after the return of spontaneous circulation 
and before randomization, evidence of hypotension (mean arterial pressure, less than 60 mm Hg) 
for more than 30 minutes after the return of  spontaneous circulation and before randomization, 
evidence of hypoxemia (arterial oxygen saturation, less than 85 percent) for more than 15 
minutes after the return of spontaneous circulation and before randomization, a terminal illness 
that preceded the arrest, factors that made participation in follow-up unlikely, enrollment in 
another study,  the occurrence of cardiac arrest after the arrival of emergency medical personnel, 
or a known preexisting coagulopathy.5 
 The patients in the study that were randomly assigned to the group receiving therapeutic 
hypothermia, had a median interval of ~105 minutes between the return of spontaneous 
circulation and the initiation of cooling. The median interval between the return of spontaneous 
circulation and when the target temperature of between 32°C and 34°C was reached was ~8 
hours. Unfortunately, the target temperature could not be reached in 19 patients.5 Some of the 
complications that arose from the study included bleeding, pneumonia, sepsis, pancreatitis, renal 
failure, hemodialysis, pulmonary edema, seizures, lethal or long-lasting arrhythmias, and 
pressure ulcers. Despite a variety of complications that arose, the proportion of patients with 
complications did not greatly differ from the hypothermic group and the normothermic group. 
Seventy-three percent of patients in the hypothermic group suffered from complications, while 
70 percent of patients in the normothermic group reported complications. The greatest difference 
between the two groups was related to the complication of sepsis, although not statistically 
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significant, with incidences reported in: 7 percent normothermic group and, 13 percent in the 
hypothermic group.5 The risk of bias assessment is discussed in Appendix C. 
Neurological outcome 
 Good neurological outcome within 6 months was found in 55 percent of the patients that 
received therapeutic hypothermia. In the normothermic group that did not receive therapeutic 
hypothermia 39 percent of the patients had a favorable neurologic outcome within 6 months. To 
be considered to have a favorable neurological outcome, this meant that the patient demonstrated 
a cerebral performance category of 1 (good recovery) or a cerebral performance category 2 
(moderate disability). They calculated a risk ratio of 1.40 (1.08-1.81), with a 95 percent 
confidence interval. This is shown in Table 1. It was shown that 6 patients would have to be 
treated with therapeutic hypothermia to prevent 1 unfavorable neurological outcome.5  
Morbidity and Mortality 
 The therapeutic hypothermia group had a mortality rate of 56 percent within 6 months, 
while the normothermic group had a mortality rate of 76 percent. This showed that the patients 
that were cooled had a mortality rate that was 14 percent lower than the patients that were not in 
the hypothermic group. They calculated a risk ratio for the hypothermic group of 0.74 (0.58-
0.95), with a 95 percent confidence interval. This is shown in Table 1. It was shown that 7 
patients would have to be treated with therapeutic hypothermia to prevent 1 death. The study also 
reported that most of the patients that had unfavorable neurological outcome died within 6 
months after being discharged from the hospital.5 
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Table 1: Neurologic Outcome and Mortality at Six Months 
Outcome Nonrmothermic 
No./total no. 
(%) 
Hypothermic 
No./total no. (%) 
Risk Ratio 
95% CI 
P Value 
Good neuro outcome 54/137 (39%) 75/136 (55%) 1.40 (1.08-1.81) 0.009 
Death 76/138 (55%) 56/137 (41%) 0.74 (0.58-0.95) 0.02 
Table 1: Hypothermia after Cardiac Arrest Study Group. (2002). Mild therapeutic hypothermia 
 to improve the neurologic outcome after cardiac arrest. N Engl J 
 Med, 2002(346), 549-556. 
 
Sunde et al. 
 Sunde et al. conducted a study where they designed a standardized treatment protocol for 
post resuscitation care following an out of hospital cardiac arrest. The treatment protocol that 
they designed included therapeutic hypothermia, percutaneous coronary intervention (PCI) only 
if indicated, and standardized goals for factors such as blood glucose, hemodynamics, 
ventilation, and handling of seizures.32 Since their study was a multivariate system approach, the 
patients could not be randomized to either select patients to receive therapeutic hypothermia or 
not in the emergency department and intensive care unit. Instead they compared their results to 
patients that were admitted to Ulleval University Hospital in a recently published study from a 
preceding period that Sunde was a part of.33 
  In this study, all patients included sustained return of spontaneous circulation (ROSC) in 
the emergency department after suffering out of hospital cardiac arrest (OHCA) of cardiac 
etiology. To be included they also had to be admitted to the ICU in the two-year interval for 
which they were studying. This included 61 patients in total. These patients were then compared 
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to the patients in Sunde’s previous study which also looked at patients in a two-year interval. 
This included 58 patients in total.  
 This article’s major endpoints were neurological outcome at time of discharge and 
survival after 1 year. With their overall goal of improving patient survival and good quality of 
life due to a favorable neurological outcome they created a standardized post resuscitation 
treatment protocol (see Appendix D) that was implemented and distributed to all involved 
hospital personnel. Some of the complications that arose in both the earlier control study and this 
study included general complications, pneumonia, sepsis, severe arrhythmias, and seizures.32 
They did not include bleeding complications since it was not looked at in the control study. 
There were no significant complication differences found between the groups. The risk of bias 
assessment is discussed in Appendix C. 
Neurological outcome 
 Good neurological outcome= patient demonstrated a cerebral performance category of 1 
(good recovery) or a cerebral performance category 2 (moderate disability). Good neurological 
outcome at time of discharge was found in all patients that survived and were discharged from 
the hospital of the intervention group that received therapeutic hypothermia. This included 34 
patients out of the initial 34 patients initially admitted to the ICU that survived. In the control 
group for which patients did not receive therapeutic hypothermia there was good neurological 
outcome at the time of discharge for 15 patients out of the 18 patients that survived and were 
admitted to the ICU. The intervention group initially had 69 patients that were admitted to the 
ER but 8 patients were excluded due to death before ICU admission. 61 patients were admitted 
to the ICU and 34 patients survived. In the control or normothermic group they initially had 68 
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patients that were admitte3d to the ER but 10 patients were excluded due to death before ICU 
admission. 58 patients were admitted to the ICU and 18 patients survived.  
Morbidity and Mortality 
 In the therapeutic hypothermia group, there were 34 patients out of the initial 69 patients 
with a one-year survival after discharge. Although 34 patients were alive at discharge so this 
means that 100 percent of the patients that survived discharge were alive a year later. The 
intervention group had 56 percent of their patients with one-year survival. In the control group, 
there were 15 out of the initial 68 patients with a one-year survival after discharge. This 
normothermic group had 31 percent of their patients with one-year survival.32 In conclusion all 
survivors with a favorable neurological outcome in both groups were still alive one year after 
discharge. The data shows that significantly more patients survived with a favorable outcome in 
the therapeutic hypothermia group than the control group or normothermic group.  
Bernard et al. 
 In a highly reviewed and cited study by Bernard et al, they enrolled patients over a 3-year 
period to look at patient outcomes. They examined patients suffering out of hospital cardiac 
arrest with VF (ventricular fibrillation) as their first cardiac rhythm who were comatose after 
they achieved ROSC (return of spontaneous circulation). This was a randomized controlled trial 
that was set up with the help of Melbourne EMS and 4 adjacent emergency departments and 
intensive care units. To be eligible to be included in the study the patient had to meet the 
following criteria: VF as an initial cardiac rhythm at the arrival of EMS, successful return of 
spontaneous circulation, persistent coma after the return of spontaneous circulation, and transfer 
to one of the four approved participating emergency departments. Patients were also excluded 
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from the study even if they met all of the initial criteria if there was no ICU bed available at the 
chosen hospital. A patient would initially be excluded if they met any of the following criteria: 
men with age less than 18 years old, females with age less than 50 years old (due to the 
possibility of pregnancy), cardiogenic shock (a systolic blood pressure of less than 90 mm Hg 
despite epinephrine infusion), or possible causes of coma other than cardiac arrest (such as drug 
overdose, head trauma, or cerebrovascular accident).4 
 Patients were randomly assigned to either the normothermic group (control), or the 
therapeutic hypothermia group (treatment). After meeting inclusion criteria, there were initially 
84 patients selected for this study. Seven patients were excluded from the study due to either 
being transferred to another hospital that was not participating in the study or due to the next of 
kin refusing consent for data collection. Of the remaining 77 patients that met inclusion criteria, 
34 patients were assigned to the control/normothermic group, and 43 patients were assigned to 
the treatment/therapeutic hypothermic group. If patients were assigned to the treatment group 
EMS would initiate the cooling by placing ice packs around the head, neck, torso, and limbs. If 
patients were assigned to the control group EMS would provide standard therapy without 
therapeutic hypothermia. After initial stabilization of the patient in the emergency department, 
the patient was admitted to the ICU and a pulmonary artery catheter was inserted. The target core 
temperature for the treatment group was 33◦C which needed to be maintained over a 24-hour 
period.4 After the 24-hour cooling period the patients underwent a 8 hours of passive rewarming. 
After rewarming the treatment group patients received standard intensive care unit protocols 
which mirrored those patients in the control group. The risk of bias assessment is discussed in 
Appendix C. 
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Neurological outcome 
 Examining patients in the treatment group, 21 of the 43 patients that underwent 
therapeutic hypothermia had good neurological outcome at the time of discharge. The control 
group had 9 patients out of the 34 that were discharged with good neurological outcomes. In the 
treatment group out of the 43 patients, 15 patients had normal of minimal disability (good 
ADLs/able to take care of themselves) and were discharged directly to home. 6 patients had 
moderate disability and were discharged to a rehab facility. In the control group, out of the 34 
patients, 7 patients had normal of minimal disability (good ADLs/able to take care of 
themselves) and were discharged directly to home. Two patients had moderate disability and 
were discharged to a rehab facility, 1 patient had severe disability (awake but completely 
dependent) and were discharged to a long-term care facility, and 1 patient was unconscious with 
a severe disability and discharged to a long-term care facility. Forty-nine percent of the 
therapeutic hypothermic patients had good neurological outcomes in comparison to 26 percent of 
the normothermic patients.4 
Morbidity and Mortality 
 Examining patients in the treatment group, 21 patients survived to be discharged from the 
hospital that underwent therapeutic hypothermia. In the control group, 11 patients survived. 
Some factors that were found to have affected outcome were age, time from collapse to return of 
spontaneous circulation, and CPR administrated by a bystander. It was found that for each 2-year 
increase in age there was a 9 percent decrease in likelihood of a good outcome or survival. An 
odds ratio was calculated: 0.91; 95 percent confidence interval, 0.84 to 0.98; P=0.014.4 
Consequently, for each additional 1.5 minutes from the time of collapse to the time of return of 
spontaneous circulation there was a 14 percent decrease in the likelihood of a good outcome or 
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survival. An odds ratio was calculated: 0.86; 95 percent confidence interval, 0.78 to 0.94; 
P=0.001. CPR administered by a bystander was found to be associated with a nonsignificant 
improvement in outcome as well. An adjusted analysis for base-line differences in age, time of 
collapse to time of return of spontaneous circulation, the odds ratio for good outcome in the 
treatment/ therapeutic hypothermia group compared to the control/ normothermia group was 
5.25.4 In the data for mortality the patients that underwent therapeutic hypothermia totaled at 51 
percent and the patients that were not cooled totaled at 68% for death. This showed that the 
difference in mortality rates between the treatment group and the normothermia group did not 
reach statistical significance (P=0.145).4 
Discussion 
 Limited randomized clinical trials have been conducted to study the use of therapeutic 
hypothermia in the setting of cardiac arrest patients. The studies that have been performed look 
to determine effectiveness in reducing neurological deficits and mortality. The use of therapeutic 
hypothermia is not yet the standard of care among health care providers in the United States. 
Although, through this clinical review it has shown great promise in displaying the increased 
chance of survival and good neurological outcome of cardiac arrest patients that have underwent 
therapeutic hypothermia. Granted there are limitations of these studies along with their strengths.  
 The results of the Holzer at al. study showed that for the patients in their treatment group 
which received therapeutic hypothermia for the 24 hours did show to have an increased chance 
of survival as well as better neurological outcomes. These results were compared to the patients 
that did not receive any cooling and were treated with standard life support protocols. There also 
wasn’t a great significant difference in rate of complications between the treatment and control 
group. The overall benefit of therapeutic hypothermia surpassed the possible adverse effects of 
	19	
	
receiving the therapy. While there are many strengths of this study that is not to say that it was 
without limitations.  
 A limitation of this study was that the health care providers taking care of the patients in 
the study could not be blinded to whether the patient was chosen to be in the control or the 
treatment group. This is to be expected considering the nature of this study. Although a patient 
may be randomly assigned to the treatment group, the health care team could not be blinded to 
their treatment due to the fact that after cooling was initiated it would need to be continued in the 
ICU as well as the rewarming phase. Another limitation of this study was the small sample size. 
Due to the importance of eligibility criteria it was found that only 8 percent of all patients that 
were initially assessed for inclusion were actually included in the study.5 
 The results of the Sunde et al. study showed when using their standardized post 
resuscitation care treatment protocol that included therapeutic hypothermia patient outcomes 
improved. The authors were looking at survival to hospital discharge with favorable neurological 
outcomes and well as one-year survival rates. Their survival rates were high in comparison to the 
survival rates of the previous results reported. The reported a 56 percent32 survival rate at 
hospital discharge with good neurological outcomes and a one-year survival among the patients 
that had out of hospital cardiac arrest that were admitted to the ICU. While their findings are 
very encouraging for the benefits of implementing therapeutic hypothermia in the standard of 
care for these patients, limitations were not absent.  
 One limitation that was found was patients that were included in the treatment group 
phase of the study to receive therapeutic hypothermia were found to be younger than the patients 
in the control phase. It was reported that the younger age could be a huge factor associated with 
the improved survival rates and improved neurological outcome. Although, it was calculated that 
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the mean age for both groups was below 70 years of age.32 Another limitation was the patients in 
the study could not be randomized for this study. If eligible patients were admitted to the 
participating hospitals during the treatment phases when the new protocol had been initiated they 
would receive therapeutic hypothermia. Since these participating hospitals had been trained on 
the new protocol and may have had increased enthusiasm for this new treatment plan it was 
thought that this could influence good patient outcomes. While staff enthusiasm cannot be 
controlled this has to be included as a possible limitation of the study.   
 The results of the Bernard et al. study showed that not only did the patients in the 
treatment group that received therapeutic hypothermia have better outcomes than the patients in 
the control group but their results also suggested that the use of therapeutic hypothermia did not 
seem to show any association to significant adverse effects.4 This evidence of no increased 
clinically significant adverse reactions is very important information to gain from the study. 
Since the use of therapeutic hypothermia in cardiac arrest is not entirely implemented in the 
United States yet, it is important to look at the evidence that shows it does not have any 
increased harm to patients.  It is important to note that their study looked at cooling for 12 hours 
but nothing beyond that time frame. While there are many strengths of this study and it was a 
major strength to also show no increase in adverse effects, like other studies reviewed this study 
was not without limitations.  
 Much like other studies in the treatment of cardiac arrest patients, a limitation of this 
study was being unable to blind the health care providers from whether a patient was in the 
treatment or control group. Another limitation of the study was the out of hospital randomization 
of patients in the designated emergency medical systems.4 The found this to be very challenging 
and their solution to this was to use the method of odd or even days to attempt to randomize the 
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patients into either the treatment group that received therapeutic hypothermia or the control 
group which received standard protocol management. Despite their studies limitations, they 
concluded that induced hypothermia does improve patient outcomes in those patients that are 
comatose after resuscitation from out of hospital cardiac arrest.4 
Conclusion 
 While patients resuscitated from cardiac arrest remain at high risk of neurologic deficits 
or death, huge strides are starting to be implemented to try to improve these outcomes. 
Therapeutic hypothermia has been demonstrated to help improve survival rates and improve 
better neurological outcomes. Not only has it been shown to improve patient outcomes, it also 
has not been shown to cause increased adverse effects. With the use of high quality critical care 
during cardiac arrest and after the return of spontaneous circulation, this care based on the most 
recent evidence based results will improve patient outcomes. Although more studies are needed 
to make the use of therapeutic hypothermia evidence stronger. The optimal core temperature of 
cooling to result in the best possible patient outcome needs further studies and evaluations. 
 Along with looking into the optimal temperature, the duration of the cooling needs to also 
be studied more. There is not enough evidence on different durations of therapeutic hypothermia 
to make an evidence based decision on duration of cooling prior to the rewarming phase. 
Another area of evidence that needs further studies is patients that suffer in hospital arrest and 
patients that suffer cardiac arrest that is not due to reasons of cardiac etiology. After more studies 
show good evidence for the use of therapeutic hypothermia in adults the next population that 
needs to be studied is the effect on children. Although more research needs to be done to make 
therapeutic hypothermia implemented across all cardiac arrest patients, current research has 
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suggested that therapeutic hypothermia implantation in cardiac arrest protocols can prove to be 
extremely beneficial in improving patient survival rates and neurological outcomes. 
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Appendix A 
 
PubMed 
  
“hypothermia, induced; patients; heart arrest; mortality, heart arrest; hypothermia, induced; 
patients, heart arrest; resuscitation; cardiovascular system” 
 
Cochrane Review Database 
 
“Induced hypothermia, Hypothermia, Induced, Therapeutic Hypothermia; Hypothermia, 
Therapeutic; Induced Hypothermia; Moderate Hypothermia, Induced; Induced Moderate 
Hypothermia; Induced Moderate Hypothermias; Moderate Hypothermias, Induced; Mild 
Hypothermia, Induced; Induced Mild Hypothermia; Induced Mild Hypothermias; Mild 
Hypothermias, Induced, Heart Arrest, Induced, Induced Heart Arrest; Cardiac Arrest, Induced; 
Induced Cardiac Arrest, Hyperthermia, Induced, Induced Hyperthermia; Therapeutic 
Hyperthermia; Hyperthermia, Therapeutic, Heart Arrest,  Arrest, Heart; Cardiac Arrest; Arrest, 
Cardiac; Cardiopulmonary Arrest; Arrest, Cardiopulmonary, Neurologic Manifestations, 
Neurological Manifestations; Manifestations, Neurological; Manifestation, Neurological; 
Neurological Manifestation; Neurologic Deficits; Deficit, Neurologic; Deficits, Neurologic; 
Neurologic Deficit; Focal Neurologic Deficits; Deficit, Focal Neurologic; Deficits, Focal 
Neurologic; Focal Neurologic Deficit; Neurologic Deficit, Focal; Neurologic Deficits, Focal 
Death, Sudden, Cardiac, Sudden Cardiac Death; Cardiac Death, Sudden; Death, Sudden Cardiac; 
Cardiac Sudden Death; Death, Cardiac Sudden; Sudden Death, Cardiac; Sudden Cardiac Arrest; 
Arrest, Sudden Cardiac; Cardiac Arrests, Sudden; Cardiac Arrest, Sudden. Cardiopulmonary 
Resuscitation, Resuscitation, Cardiopulmonary; Cardio-Pulmonary Resuscitation; Cardio 
Pulmonary Resuscitation; Resuscitation, Cardio-Pulmonary; Mouth-to-Mouth Resuscitation; 
Mouth to Mouth Resuscitation; Mouth-to-Mouth Resuscitations; Resuscitation, Mouth-to-
Mouth; Resuscitations, Mouth-to-Mouth; Basic Cardiac Life Support; Life Support, Basic 
Cardiac.” 
 
Embase 
 
('induced hypothermia'/exp OR 'induced hypothermia') AND therapeutic AND 
('hypothermia'/exp OR hypothermia) AND ('cardiovascular'/exp OR cardiovascular) AND 
('resuscitation'/exp OR resuscitation) AND cardiac AND ('arrest'/exp OR arrest) AND deficits 
AND neurological AND ('outcome'/exp OR outcome) AND ('mortality'/exp OR mortality) 
 
Trip database 
 
(Cardiac arrest patients)(therapeutic hypothermia)(standard icu protocol)(reduced mortality) 
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Appendix B 
 
Table 1: Potential mechanisms of action, risks and changes with hypothermia 
	
Mechanism/change 																						Explanation 														When/treatment 
Metabolic changes 
 
 
 
 
 
 
 
Electrolytes  
 
 
 
 
 
 
 
 
 
Apoptosis and  
  mitochondrial 
   dysfunction 
 
 
 
 
 
 
 
 
 
 
Ion pumps and 
Neuro 
excitotoxicity 
 
 
 
 
 
 
 
 
 
 
 
 
↓ Cerebral metabolic rate by 6–8% per 1◦ C 
↓ in core T →↓ in O2 consumption and 
CO2 production. Excessive ↑ in CO2 can 
↑cerebral edema, and excessive ↓ in CO2 
can   ↑ ischemia. 
 
Cooling → ↑ renal tubular dysfunction → 
↑ electrolyte excretion. Cooling → 
intracellular electrolyte shift → ↓ K+, 
Mg2+, PO4- →↑  risk for arrhythmias. 
Rewarming → intracellular K+ released → 
hyperkalemia 
 
Post IR injury mitochondrial dysfunction 
(mitochondria = cells’ energy source), 
disturbed energy metabolism in cell, and 
caspase enzymes can → apoptosis 
Hypothermia blocks apoptotic pathway 
early by: ↓ caspase enzyme activation, ↓ 
mitochondrial dysfunction, ↓ excitatory 
neurotransmitters, and modifying 
intracellular ion concentrations 
 
IR injury → ↓ brain O2 supply → quick ↓ 
in ATP and phosphocreatine levels. This 
initiates a complex cascade of events 
involving excessive calcium influx into 
brain cells, excessive glutamate receptor 
activation and neuronal hyperexcitability 
(excitotoxic cascade) which can lead to 
further injury and cell death even after 
reperfusion and normalization of 
glutamate levels. Hypothermia can ↓ 
damage from neuroexcitatory cascade 
Acute in induction/frequent BGs and 
ventilator setting adjustments to 
maintain normocapnia, slow rewarming 
 
 
Keep electrolytes in high-normal range, 
slow rewarming (0.25◦C/h post cardiac 
arrest, slower for severe TBI) 
 
 
 
Starts late in post-reperfusion phase, can 
continue for 72 h or more → In theory 
wide window for treatment 
 
 
 
 
 
Disturbed Ca2+ homeostasis begins 
minutes after injury and may continue 
for many hours → may be treatable. 
Animal studies suggest to initiate 
treatment early in the neuroexcitatory 
cascade 
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Inflammation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Free radials 
 
 
 
 
 
 
 
 
 
Blood-brain 
   Barrier/vascular 
   permeability 
 
 
 
 
 
 
 
 
 
 
 
 
Acidosis and cellular 
   Metabolism 
 
 
 
 
 
 
 
Brain injury → Proinflammatory 
mediators released ++ → leukocytes 
drawn across BBB → ↑ inflammatory cells 
in brain → passage of neutrophils, 
phagocytic monocytes and macrophages 
into brain → phagocytic action and toxin 
production → further injury by stimulating 
further immune reactions. Some of this is 
neuroprotective, but if continual and 
excessive → ↑ injury. Hypothermia → ↑ 
ischemia-induced inflammatory and 
immune reactions, ↓ NO production (key 
agent in developing brain injury post-
ischemia), ↓ neutrophil/macrophage 
function and ↓ WCC 
 
IR injury → ↑ free radicals that oxidize 
and damage cell components → brain’s 
defense mechanisms likely overwhelmed. 
Hypothermia → ↑ release of free radicals 
→ endogenous antioxidants more able to 
meet demand 
 
Traumatic/IR injury can disrupt BBB → 
brain edema. Mild hypothermia ↓ BBB 
disruptions and vascular permeability after 
IR injury →↓ brain edema. Brain edema 
and ICH play key role in neurological 
injury in severe TBI and ischemic stroke, 
and ICH is a marker for neurological 
injury → plausible that therapies to ↓ ICP 
may also improve neurological outcome 
Hypothermia has been used to ↓ ICP in 
neurological injury including TBI, 
ischemic stroke, meningitis and SAH 
Ion-pump failure, mitochondrial 
dysfunction, cellular hyperactivity and ↓ in 
cell membrane integrity → intracellular 
acidosis → ↑ harmful processes. 
Hypothermia can alleviate this, may 
improve brain glucose metabolism and 
when induced early enhances speed of 
metabolic recovery → ↓ toxic metabolite 
accumulation → ↓ acidosis 
 
Begins ~ 1 h after ischemia and persists 
for up to 5 days, suggesting a 
therapeutic window for these 
mechanisms 
 
 
 
 
 
 
 
 
 
 
 
 
Brain edema peaks after 24–72 h → this 
mechanism could offer a wide 
therapeutic window 
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Brain temperature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vasoactive mediators 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain temperature slightly higher than core 
temperature and can ↑ 0.1–2.0 ◦C post-
injury (more with fever). Injured areas are 
hotter than uninjured areas due to cellular 
hyperactivity. Dissipation of heat by 
lymph/venous drainage is hampered by 
local brain edema (cerebral thermo-
pooling) → ↑ hyperthermia related injury 
Hypothermia in brain-injured patients may 
↓ potential hyperthermia-related adverse 
effects 
 
Activation of coagulation seems to be 
involved in developing IR injury. Its 
reversal, whilst targeting other 
mechanisms, could improve outcomes 
Hypothermia induces anticoagulatory 
effects: mild platelet dysfunction at 33–35◦ 
C; can affect clotting factors at ≤ 33◦C, and 
a potential reduction in platelet count, may 
influence synthesis and kinetics of clotting 
enzymes and plasminogen activator 
inhibitors. This anticoagulation effect 
could provide protection, but not 
investigated. Cooling to 35◦ C – no effect 
on coagulation 
 
Secretion of vasoactive substances 
endothelin and TxA2 (vasoconstrictors) 
and prostaglandin I2 (vasodilator) is 
affected by hypothermia. TxA2 and 
prostaglandin I2 regulate cerebral blood 
flow. Their balanced production is 
required to maintain homeostasis. If 
disrupted by ischemia/trauma TxA2 
production increases which can → 
vasoconstriction and hypoperfusion in 
injured brain. Hypothermia → ↓imbalance, 
but regulation of cerebral perfusion is 
complex and influenced by cerebral 
autoregulation and patient management. 
Influence of hypothermia on secretion of 
 
 
 
 
 
 
 
 
 
 
 
Assess risk versus benefit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	30	
	
 
 
 
Improved tolerance 
   of ischemia 
  (pre-conditioning) 
 
 
 
 
 
Reduction of epileptic 
   activity 
 
 
 
 
 
 
 
 
 
Early gene activation 
 
 
 
 
 
 
 
Shivering 
 
 
 
Insulin sensitivity 
  and secretion 
 
Cardiovascular/ 
   hemodynamic 
   effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vasoactive mediator in brain-injured 
patients requires further investigation 
In animal models ‘preconditioning’ with 
hypothermia improves tolerance for 
ischemia. As brain injury is frequently 
complicated by ischemic events after the 
initial insult, this could be a valuable 
neuroprotective mechanism 
Epileptic activity without signs and 
symptoms (non-convulsive) occurs 
frequently in brain-injured patients and if 
it occurs in the acute phase of brain injury 
the combined effect is destructive. 
Evidence indicates that hypothermia # 
epileptic activity; another mechanism 
through which it could provide 
neuroprotection 
Hypothermia → ↑ early gene activation 
which is part of the protective cellular 
stress response to injury and → ↑ 
production of cold shock proteins that can 
be cryoprotective in the presence of 
ischemic and traumatic injury 
↑ metabolic rate, O2 consumption, work of 
breathing, heart rate and myocardial O2 
consumption 
↓ with cooling → hyperglycemia or ↑ 
insulin required 
Mild hypothermia: In euvolemic, 
adequately sedated pts ↓  HR, ↑ 
myocardial contractility, → or slightly ↑ 
BP, ↓ CO. ↓ metabolic rate matches or 
exceeds ↓ CO → balance maintained 
Initial transient ↑ HR due to ↑ venous 
return (↑ if sedation inadequate, shivering 
untreated) Stabilizes cell membranes → ↓ 
risk of arrhythmias, ↑ successful 
defibrillation. Deep hypothermia: (≤30◦C) 
↓ contractility, ↑ risk for arrhythmias, ↓ 
successful defibrillation, ↓ response to 
antiarrhythmics Cold diuresis: the result of 
↑ venous return (due to peripheral vessel 
constriction), atrial natriuretic peptide 
activation, ↓ ADH and renal ADH receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34–35◦ C/opiates, sedation, paralysis if 
required, other agents 
Induction and rewarming/frequent BGL 
checks and insulin adjustments, slow 
rewarming 
 
Sedate adequately  
Allow ↓ HR 45–55 at 33◦C (artificial ↑ 
HR → ↓ contractility)  
Avoid and correct hypovolemia. Avoid 
stimulating HR 
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Coronary perfusion 
 
 
 
 
 
 
 
 
 
Drug clearance 
 
 
 
 
 
 
 
 
Infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gut 
 
 
levels, and tubular dysfunction → 
hypovolemia.  
↓ metabolic rate and HR protects ischemic 
myocardium, ↑ coronary vasodilation and 
perfusion. But in severely atherosclerosed 
coronaries, vasoconstriction can occur → 
may affect result of hypothermia  
Shivering can ↑ myocardial O2 
consumption 
Most enzyme-based reactions slowed → ↓ 
drug clearance by liver. Tubular 
dysfunction may also affect clearance, and 
response to some drugs alters e.g. ↓ effect 
of adrenaline and noradrenaline. BUT 
most drug levels ↑ → ↑strength and 
duration of effect 
↓ leukocyte migration and phagocytosis, ↓ 
proinflammatory cytokine synthesis → ↓ 
proinflammatory response → may protect 
against damaging neuroinflammation, but 
↑ risk for infection (↑ risk with ↑ duration) 
↑ risk for wound infection due to 
cutaneous vasoconstriction  
Signs of infection: e.g. fever and possibly 
CRP and WCC ↓. 
 
↓ gut function and gastric emptying, ↓ 
metabolic rate 
 
 
 
 
 
 
 
Sedate adequately-prevent shivering 
 
Modify doses of certain drugs 
 
 
Low threshold for antibiotic treatment 
may be advisable 
 
↑ in ‘cooling power’ required may 
indicate fever and infection 
 
 
Reduce feeding target in maintenance 
phase 
	
	
 
 
 
 
↓: decrease (d), →: leads to, ↑: increase (d), T: temperature, O2: oxygen, CO2: carbon dioxide, BGs: blood gases, IR: ischemia reperfusion, ATP: 
adenosine triphosphate, Ca2+: calcium, BBB: blood–brain barrier, NO: nitric-oxide, WCC: white cell count, ICH: intracranial hypertension, ICP: 
intracranial pressure, TxA2: thromboxane A2, ◦C: degrees Celsius, BGL: blood glucose level, K+ : potassium, Mg2+: magnesium, PO4- : phosphate, 
TBI: traumatic brain injury, HR: heart rate, BP: blood pressure, CO: cardiac output, ADH: antidiuretic hormone, CRP: C-reactive protein. 
Table 1: Moore, E. M., Nichol, A. D., Bernard, S. A., & Bellomo, R. (2011). Therapeutic 
hypothermia: benefits, mechanisms and potential clinical applications in neurological, 
cardiac and kidney injury. Injury, 42(9), 843-854 
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Appendix C 
 
The Cochrane Risk of Bias Tool was my quality evaluation choice.  
 Holzer at al. 
 
Sunde at al. 
 
Bernard at al. 
 
Selection bias Treatment 
assignments were 
randomly generated 
by computer in 
blocks of 10 
The patients in this 
study could not be 
randomized. They 
were either in the 
control group (1st 
phase), or the 
treatment group (2nd 
phase) 
 
The patients were 
randomized using the 
method of odd and 
even days. Despite 
the potential for bias 
in randomization, it 
appears that the two 
patient groups were 
comparable. 
Performance bias Patient care providers 
involved in the care 
of patients during the 
first 48 hours after 
cardiac arrest could 
not be blinded with 
respect to treatment 
assignments. 
Physicians 
responsible for 
assessing the 
neurologic outcome 
within the first six 
months after the 
arrest were however 
blinded of the 
patients treatment 
assignment 
 
Treatment 
assignment could not 
be blinded. Medical 
providers were not 
blinded to patient 
treatment plans. 
Possible bias due to 
increased awareness 
and enthusiasm for 
the new treatment 
approach 
Treatment 
assignment was not 
blinded. It was not 
feasible to blind 
medical providers to 
the patients' treatment 
group assignments. 
There is a possibility 
that bias could have 
affected patient care 
and outcome 
Detection bias Physicians 
responsible for 
assessing the 
neurologic outcome 
within the first six 
months after the 
arrest were blinded of 
the patients treatment 
assignment 
Physicians 
responsible of patient 
care were not blinded 
of their patients 
outcome, however 
they were blinded to 
the patient outcomes 
in the control phase 
Patient was 
discharged by a rehab 
center physicians 
who was unaware of 
initial treatment 
protocols and were 
blinded to the 
outcome due to being 
unaware of group 
selection 
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Attrition bias Minimal incomplete 
outcome data 
reported 
Minimal incomplete 
outcome data 
reported 
Minimal incomplete 
outcome data 
reported 
Reporting bias No evidence of 
selective outcome 
reporting found 
No evidence of 
selective outcome 
reporting found 
No evidence of 
selective outcome 
reporting found 
Other The requirement of 
informed consent was 
waived in accordance 
to ethical standards 
and local guidelines. 
The patient’s family 
was informed about 
the trial, and the 
studies protocol 
stated that if there 
were any protests, the 
patient would be 
withdrawn from the 
study. 
 
Written consent to be 
included in this study 
could not be obtained 
from patient. Written 
informed consent for 
participation in this 
study was sought 
from the next of kin 
as soon as possible 
after the arrival of the 
patient at the hospital. 
Also there could be 
possible bias due to 
conflict of interest 
since Dr. Sunde 
received research 
grants from Laerdal 
Foundation for Acute 
Medicine and 
Professor Steen 
is a member of the 
Board of Laerdal 
Medical. 
Written consent to be 
included in this study 
could not be obtained 
from patient. Written 
informed consent for 
participation in this 
study was sought 
from the next of kin 
as soon as possible 
after the arrival of the 
patient at the hospital. 
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Appendix D 
 
Standardized post resuscitation treatment protocol 
 
 
In hospital standardized treatment plan after ROSC at Ulleval 
University Hospital Goal: to reduce the vital organ injuries (brain, 
heart), through: 
1. Initial optimizing hemodynamics and oxygenation 
2. (a) Treat the cause of arrest; reperfusion (PCI) after STEMI and 
(b) Therapeutic hypothermia (33 ◦C in comatose patients for 
24 h) Start as early as possible after decision making in the 
ED Initially 1-3 l of ice-cold 0.9% NaCl i.v. together with 
ice bags 
Endovascular cooling/external cooling for maintenance after arrival at the ICU 
3. A standardized treatment protocol for the following days 
 
3.1. Factor Goal Strategy 
Reperfusion Reperfusion PCI in STEMI 
Blood pressure MAP > 65—70 mmHg Volume, vasopressors, inotropic 
  agents, IABP 
Central venous pressure 8—12 mmHg Volume, glyceryl trinitrate, 
  diuretics 
ECG, rate/ischemia 60—100/min Volume, sedation, glyceryl 
  trinitrate, beta-blocker (normally 
  not indicated when using 
  therapeutic hypothermia because 
  of relative bradycardia) 
Temperature 33 ◦C for 24 h Initially ice cold (4 ◦C) NaCl 0.9% 
i.v. 
  and icepacks, then 
  internal/external cooling device 
Ventilator SpO2 95—98 Respiratory control, FiO2, PEEP 
 pCO2 5—6 kPa (NB! Avoid hyperventilation) 
Blood glucose 5—8 mmol/l Actrapid-infusion (NB! Avoid 
  hypoglycemia/hypokalemia) 
Electrolytes Normal values Replacement/specific treatment 
Hemoglobin >9—10 g/dl Transfusion if necessary 
Diuresis >1 ml/kg/h Volume, diuretics or pressors 
Buffers pH > 7.1, BE >−10 When indicated, trometamol 
125—250 ml i.v. 
Seizures Prevent/treat seizures Increase sedation, or specific 
           anticonvulsive medication 
           EEG when indicated (early contact 
           with a neurologist) 
 
 
 
 
3.2. Sedation 
Fentanyl and propofol (paralysis when indicated with cisatracurium/pancuronium) 
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3.3. Monitoring 
Arterial 
catheter O2-
saturation 
Continuous 
ECG 
Central venous line with central venous pressure 
Temperature (bladder) 
Arterial blood gases (pH, BE, pCO2, 
pO2) Blood glucose and electrolytes 
Echocardiography, chest X-ray 
EEG and SEP 
 
3.4. Vasopressors/inotropic agents  
       First choice: dopamine                                If tachycardia, check volume status,                       
         (2—10 µg/kg/min)                                      or change to noradrenaline 
             (norepinephrine)  
             (0.02—.3 µg/kg/min) 
                                                                            
 
        If pump failure/cardiogenic shock                IABP 
                                                                          Dobutamine (2—10 µg/kg/min) and if necessary adrenaline 
                                                                         (epinephrine)(0.02—0.3 µg/kg/min) 
                                                                         (levosimedane as last resort) 
 
 
 
 
3.5. Awakening protocol/respirator weaning 
After 24 h of cooling, patients should be slowly rewarmed (0.5 ◦C/h). Sedation may be stopped after the 
body temperature has reached 35.5 ◦C. Extubation using normal indications. Avoid long term ventilator 
treatment (if no complications are present) 
 
 
 
 
 
 
 
 
Sunde, K., Pytte, M., Jacobsen, D., Mangschau, A., Jensen, L. P., Smedsrud, C., ... & Steen, P. 
A. (2007). Implementation of a standardised treatment protocol for post resuscitation care 
after out-of-hospital cardiac arrest. Resuscitation, 73(1), 29-39. 
 
